In this study, simultaneous positron emission tomography (PET)/magnetic resonance (MR) imaging was employed to evaluate the feasibility of the PET tracers 2-deoxy-2-18
H UMAN PAPILLOMAVIRUSES (HPVs) are the causative agents for cervical cancer and have been implicated in other anogenital cancers and a subset of head and neck carcinomas. [1] [2] [3] [4] Cervical cancer is the third most frequent cancer in women worldwide. It is estimated that approximately 530,000 women developed cervical cancer and 275,000 died by reason of the disease in 2008. 1 Twelve high-risk HPV types recognized as class I carcinogens by the World Health Organization are necessary risk factors for the development of cervical cancer. 2 HPV has also been linked to the development of nonmelanoma skin cancer, which represents the most common malignancy in whites worldwide. 5 An excellent animal model to study papillomavirus-induced cancer formation in vivo is the New Zealand White (NZW) rabbit, where infections with cottontail rabbit papillomavirus (CRPV) cause the development of skin tumors within 4 to 6 weeks postinfection, which then progress to invasive cancer without additional cofactors within 8 to 14 months. 6, 7 Although skin tumor progression may be directly evaluated by visual inspection, the depth and progression of subcutaneous invasion and its temporal molecular changes are difficult to assess. In this study, we used a simultaneous positron emission tomography (PET)/magnetic resonance (MR) system 8 to combine anatomic and molecular information for more precise analyses of skin tumor growth or regression 9 to develop a noninvasive method of monitoring papillomavirus-induced skin tumor growth in CRPV-infected NZW rabbits. This study aimed at identifying suitable tracers for future studies monitoring various therapy regimens, which include the use of potential tumor-inhibiting substances.
Imaging methods, such as computed tomography (CT) or MR imaging, provide excellent morphologic information. 9, 10 One potential problem with these techniques is the lack of metabolic information, which is essential for the reliable prediction of the physiologic response of the cancer tissue to the respective treatment. Functional changes in tumor biology, such as apoptosis on treatment, occur much earlier than morphologic changes affecting the size of the tumor. 11 With this in mind, PET reveals the metabolic and functional parameters of living cells and is capable of distinguishing between normal and malignant tissues through the use of various PET tracers.
PET has previously been performed on mice with chemically induced skin tumors 12, 13 and in patients with sinonasal inverted papilloma, 14, 15 of which more than 70% are HPV negative, 16 18 F-FLT is a PET marker for cell proliferation and is consumed by proliferating cells via the salvage pathway, which incorporates nucleotides into replicating deoxyribonucleic acid (DNA) during the S phase of the cell cycle. 17 18 F-FLT is, however, rarely incorporated into the DNA 18 and has been used in preclinical and clinical studies to monitor treatment efficacy in cancers. 19 11 CCholine is another promising PET tracer that can be used to detect membrane synthesis. It is initially phosphorylated within the tumor cell. The resulting phosphatidylcholine is then trapped in the lecithin of the cell membrane. 20 Dividing tumor cells are characterized by increased cell membrane synthesis, leading to an enhanced uptake of 11 C-choline. Thus, although not directly correlated with the cellular proliferation rate, 11 Ccholine is an interesting candidate for cancer imaging where 18 F-FDG and 18 F-FLT fail. 11 C-Choline was first used for imaging brain tumors 21 and is currently employed primarily for detection and staging of prostate cancer, [22] [23] [24] [25] because of its low bladder activity. Thus, for detection of gynecologic malignancies 11 C-choline might be superior to 18 F-FDG and 18 F-FLT, which are excreted via the urinary tract, because of reduced masking of the pelvic region. 25, 26 In this study, the clinical gold standard in PET oncology, 18 F-FDG, showed a markedly increased uptake into the tumor tissue of rabbits, whereas 18 F-FLT failed. However, 11 C-choline revealed an uptake comparable to 18 F-FDG, thus representing an alternative PET tracer to 18 F-FDG for imaging papillomavirus-induced tumors.
Materials and Methods

Animal Model and Infection Procedure
Specific pathogen-free (SPF) female NZW rabbits were obtained from Charles River (Kisslegg, Germany) and were maintained in an SPF facility under standard environmental conditions (18 6 2uC room temperature, 50 6 10 % relative humidity, 12-hour light/dark cycle). The rabbits were anesthetized using 35 mg of ketamine hydrochloride and 0.25 mg of medetomidine hydrochloride per kilogram body weight. The infection sites at the flanks of the rabbits were marked, and viral DNA was injected into the skin using a Helios Gene Gun (BioRad, Munich, Germany) as described previously. 27, 28 Animal experiments were approved by the review board for animal experiments (permission no. H1/08).
Simultaneous PET/MR Imaging
Simultaneous PET/MR imaging was performed using the human BrainPET system (Siemens Healthcare, Knoxville, TN), which allows nearly whole-body scans of the rabbits. The BrainPET PET/MR system consists of an MRcompatible PET system inserted into a modified 3 T MR scanner (Magnetom Tim Trio, Siemens Healthcare). The technical specifications of the PET system have been described previously. 29 The . All image data were acquired in list mode for retrospective data rebinning and reconstruction.
CRPV-infected NZW rabbits were imaged at 2, 4, and 10 months postinjection under anesthesia using the PET tracers 18 F-FDG (50-60 MBq), 18 F-FLT (50-60 MBq), and 11 C-choline (100-110 MBq), which were injected via an ear vein catheter. The imaging schedule contained the consecutive measurement of one cohort of rabbits during 1 week (day 1:
18 F-FLT; day 3: 11 C-choline; day 5: 18 F-FDG), which allowed us to significantly reduce the number of animals used in this study according to the guidelines of animal care. For all tracers, 30-or 60-minute dynamic PET scans were performed. The 30-minute scans started after an uptake time of 30 minutes and the 60-minute scan directly during tracer injection. Simultaneously to the PET acquisition, the MR examination protocol was performed, which included gradient-echo localizers, transverse T 1 -weighted three-dimensional spoiled gradient echo PET attenuation maps for scatter and attenuation correction were computed from the FLASH image. To remove artifacts in the MR image originating from the living animal, for example, breathing and heart motion, a combination of thresholding, morphologic operations, and connected component analysis was employed. After thresholding the MR image and shrinking connected regions to remove small artifacts, only the largest connected region was retained, discarding larger MR motion artifacts outside the rabbit. The MR image was then segmented into four classes by intensity thresholding, assigning the corresponding CT values (air, 21,000 HU; lung, 2650 HU; fat, 270 HU; soft tissue, 50 HU). Image smoothing was performed using a gaussian filter (5.625 mm full width at half maximum), and the assigned CT values were converted to linear attenuation coefficients at 511 keV (yielding air 0 cm -1 , lung 0.0336 cm -1 , fat 0.08928 cm -1 , and soft tissue 0.10065 cm -1 ). PET listmode files were rebinned into multiple frames depending on the tracer. PET data were reconstructed using a three-dimensional ordered subset expectation maximization (OSEM) algorithm (6 iterations, 16 subsets) and resolution modeling using the software provided by the manufacturer. Corrections for randoms, attenuation, and scatter were applied.
PET images were analyzed using Inveon Research Workplace software (Siemens Preclinical Solutions, Knoxville, TN). Data sets from PET/MR were coregistered, and regions of interest (ROI) were drawn around the viable papilloma tissue, based on the anatomic information from the MR images and the molecular information of the PET. Volumetry of the viable tumor tissue was assessed from the PET/MR data obtained by the 18 F-FDG imaging using these ROI. Absolute quantification as a percentage of the injected dose or standard uptake values (SUVs) of the PET data sets was not possible in this study because the BrainPET was not cross-calibrated. Therefore, the uptake of the tracers used is expressed as a ratio of tumor to muscle or tumor to liver uptake.
PET/CT Imaging
To enable quantification and report clinically relevant SUVs, 11 C-choline-PET/CT was performed for two animals using a clinical scanner. PET data acquisition (Hi-Rez Biograph 16, Siemens Healthcare) was initiated 50 minutes after injection of 11 C-choline (50-60 MBq) and lasted for 4 minutes (one bed position). For attenuation correction, a non-contrast-enhanced low-dose CT scan was acquired, and CT for the anatomic information was sequentially performed. Attenuation-corrected trans-axial slices (matrix size 256 3 256, corresponding to a FOV of 45.5 cm 3 45.5 cm) were reconstructed using the standard software of the scanner (Fourier rebinning, two-dimensional OSEM with 8 iterations, 16 subsets, 5 mm gaussian filter). PET/CT images were analyzed and compared to PET/MR images.
Ex Vivo Biodistribution
Following the final 18 F-FDG PET scan, the animals were euthanized by injection of T61 (Intervet, Unterschleissheim, Germany) under deep anesthesia and were subsequently dissected. Tumors and organs were removed and measured together with an aliquot of the injected radiotracer solution by gamma-counting (Wizard singledetector gamma-counter; PerkinElmer, Waltham, MA) using an energy window of 350 to 650 keV. The results are expressed as percent injected dose per gram (% ID/g) of tissue.
Statistical Analysis
Statistical analysis was performed using analysis of variance (ANOVA) with a post hoc Bonferroni test carried out with Origin 8 software (OriginLab Corporation, Northampton, MA). Data were considered statistically significant for p , .05. All quantitative results are shown as the mean 6 1 standard deviation (SD).
Results
PET/MR Imaging and Biodistribution
Tumors induced by CRPV are depicted at different time points in Figure 1 . At 2 months postinfection, small papillomas are visible in the inoculated skin on the back of the rabbits (see Figure 1A) , which successively progress to larger tumors (see Figure 1, B-D) . To monitor tumor growth in the rabbits noninvasively, the animals were imaged using the PET tracers 18 Figure 2 shows a representative rabbit at 10 months postinjection. The imaging results are presented as CRPV-induced tumor to organ ratios in Figure 3 .
The glucose analogue 18 F-FDG showed the highest uptake values compared to the other PET tracers tested (see Figure 3A) . At 2, 4, and 10 months postinjection, we found an 18 F-FDG tumor to muscle ratio of 11.22 6 3.53 (n 5 3), 13.57 6 0.68 (n 5 5), and 16.2 6 0.91 (n 5 3), respectively. Tumor to liver ratios showed lower values compared to the tumor to muscle ratios but revealed the same trend at 2, 4, and 10 months postinjection (0.76 6 0.14, 1.11 6 0.12, and 1.31 6 0.35, respectively). 11 CCholine also showed high tumor to muscle ratios after 4 (6.69 6 1.47; n 5 4) and 10 months postinjection (6.34 6 1.04; n 5 3; see Figure 3B ), whereas, after 2 months postinjection, the 11 C-choline uptake was lower (2.73 6 1.5, n 5 2) than the uptake measured for After injection of 18 F-FDG, the time-activity curves (TACs) of the tumor uptake increased during the dynamic acquisition time of 60 minutes (see Figure 3A , right panel). The 18 F-FDG TACs of the muscle tissues remained low during the entire acquisition time, which is in agreement with previous findings, for example, in mice. 20 In contrast, the 18 F-FDG TACs of the liver tissue peaked immediately after the injection due to the high blood-pool concentration of the tracer at this early time point and declined rapidly before it reached a stable plateau after about 25 minutes acquisition time. The level (arbitrary values) was similar to the one reached in the tumor tissue, thus explaining the low tumor to liver ratios at 50 to 60 minutes after 18 F-FDG injection (see Figure 3A ). 11 C-Choline TACs showed a very low uptake into the muscle tissue, whereas values steadily increased for tumor and liver tissue. However, no plateau was reached in the TACs of the tumor or liver tissue (see Figure 3B ). 18 F-FLT uptake remained low for tumors and muscle for the entire 60 minutes of acquisition time. The liver 8 F-FLT TAC revealed a perfusion peak in the first 5 minutes after tracer injection (see Figure 3C) .
The results of the 18 F-FDG biodistribution are shown in Figure 4 . After 6 months postinjection, the organ to muscle ratios showed a relative 18 F-FDG uptake of 10.8 6 2.05 in tumor tissue, 3.55 6 0.27 in uninfected skin, 2.88 6 0.36 in blood, 7.78 6 0.17 in the liver, 9.72 6 0.64 in the spleen, 6.03 6 1.33 in the kidneys, 2.7 6 0.45 in heart muscle tissue, 6.22 6 0.92 in lung tissue, and 1.69 6 1.66 in fat (see Figure 4) . After 10 months postinjection, the organ to muscle ratios revealed an even higher relative uptake of F-FDG showed the highest uptake, but 11 C-choline uptake was also increased in tumor tissue. No uptake was observed in tumors using the proliferation marker 18 F-FLT. The figure depicts the precise coregistration of the molecular and anatomic information due to the simultaneous acquisition of PET and MR.
PET/MR Imaging of Papillomavirus Tumors in Rabbits activated immune system at this stage of infection. 
PET/CT Imaging
For quantification of the 11 C-choline uptake into tumors of CRPV-injected rabbits, PET/CT scans were performed at 10 months postinjection and were compared to PET/ MR imaging. Two animals underwent PET/CT measurements with 11 C-choline. SUVs from the 11 C-choline-PET/ CT were 1.46 6 0.02 for tumor, 0.69 6 0.02 for muscle, and 7.74 6 0.73 for liver tissue ( Figure 5 ).
Discussion
The early assessment of applied therapeutics in cancer patients is most critical to manage efficient chemotherapy and an optimal quality of life. 30 Infection of NZW rabbits with CRPV serves as an excellent animal model system to study the role of the viral oncoproteins in tumor development. In this study, we employed the animal model system for CRPV-induced tumors to evaluate the PET tracers 18 F-FDG, 18 F-FLT, and 11 C-choline for tumor detection using simultaneous PET/MR imaging. All primary tumors were detectable after 2 months postinjection in 18 F-FDG and 11 C-choline PET images, whereas 18 F-FLT failed to image CRPV-induced tumors in the rabbits.
Functional changes in tumor biology, such as apoptosis or senescence on treatment, occur much earlier than morphologic changes affecting the size of the tumor. Hence, treatment efficacy may be monitored by PET imaging combining morphologic and molecular information without applying additional radiation doses arising from CT measurements. 18 F-FDG, which is the current gold standard for oncologic PET imaging, has been shown to accumulate in normal tissue, such as the liver, due to physiologic glucose uptake and in sites of inflammation due to increased glucose metabolism. 31 We used the glucose analogue 18 F-FDG to determine whether an increased glucose uptake into the papillomavirus-induced tumors can be detected by PET imaging of CRPV-infected NZW rabbits and were able to detect tumors ever since the 2 months postinjection examined time points. However, a major drawback for the clinical application of 18 F-FDG PET is the hampered detection of HPV-associated tumors in the pelvic region due to the excretion of radioactivity into the bladder complicating the interpretation of acquired images in this area. 32, 33 Use of the tracer 11 C-choline has the advantage of not complicating imaging of pelvic tumors as it is not excreted via the bladder. Choline is incorporated into cells via phosphorylcholine synthesis and integrates into the phospholipids of cell membranes. 34 Various cancers have elevated levels of phosphorylcholine compared to the low or even undetectable levels in normal tissues. 35, 36 Indeed 11 C-choline has been used successfully in PET imaging of tumors in the pelvic region, including cervical cancer. [22] [23] [24] 26, 37, 38 Therefore, the simultaneous use of noninvasive, high-tissue contrast MR imaging in combination with 11 C-choline PET has the potential to improve diagnosis and support future clinical staging of cancers. In addition, we confirmed reports from previous studies demonstrating that the uptake of 11 C-choline into tumors was lower than the uptake of 18 F-FDG. 37, 39 Interestingly, the proliferation marker 18 F-FLT failed to detect the CRPV-induced tumors in rabbits. However, we cannot rule out that this might be due to the slow proliferation rate of the tumors, which is implicated by the low relative uptake values in the TACs over the acquisition time of 60 minutes (see Figure 3 ). To our knowledge, no commercial Ki-67 marker is available for staining rabbit tissues preventing us to proof this hypothesis by histology. Fuchs and colleagues showed recently that ketamine/ xylazine reduces 18 F-FLT uptake in carcinomas in mice. 40 Since imaging was here performed under ketamine/ medetomidine anesthesia, this could have an impact on 18 F-FLT uptake. However, the TAC indicates a rapid washout of FLT and nearly no specific binding, whereas Fuchs and colleagues found a decent uptake under ketamine/xylazine anesthesia, which was reduced (4.3 6 0.9 %ID/cc) compared to animals scanned under isoflurane anesthesia (6.4 6 1.5 %ID/cc). Therefore, the use of ketamine anesthesia might influence 18 F-FLT uptake.
In future studies, we also plan to compare the functional parameter obtained from extended MR measurements such as diffusion-weighted magnetic resonance imaging (DW-MRI) while acquiring the PET data simultaneously. This approach will allow multiparametric data analysis comparing the DW-MRI quantification via the apparent diffusion coefficient with the PET data. In this study, the aim was to evaluate clinically used tracers in the animal model of papillomavirus-induced tumors. However, future PET/MR experiments using a papillomavirusspecific antibody against a putative tumor antigen would be advantageous to distinguish between secondary inflammation reactions and tumor tissue. 31, 41 At present, we cannot ensure that the enhanced 18 F-FDG uptake in tumor In summary, our data show that papillomavirusinduced tumors in rabbits can be visualized by both 18 F-FDG and 11 C-choline.
Conclusion
This study shows the feasibility of 18 F-FDG but also of 11 Ccholine PET imaging to detect papillomavirus-induced tumors in the rabbit animal model system. It therefore provides a basis for future studies to investigate the applicability of simultaneous PET/MR imaging using the tracers 18 F-FDG or 11 C-choline in preclinical settings for tumor characterization, staging, and treatment monitoring of papillomavirus-induced cancers.
